Drug Trial Radar · NCT07168226
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
May 8, 2026
Primary completion
Apr 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- MetaFinesIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are: Can the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group? Do participants experience adverse events during administration of ASCA101 and/or within 4 weeks after the end of administration? This clinical trial comprises two parts. \[Study 1. Active-Controlled, Open-Label Study\] Participants who provide written informed consent will undergo screening procedures. Those who meet all inclusion criteria and none of the exclusion criteria will be eligible for enrollment and will be randomized to receive either ASCA101 (at one of two dose levels: 24.32 or 32.43 mg/kg) or an active control. Participants will receive the investigational product over 3 cycles (12 weeks). Each cycle consists of 28 days. Subjects in the ASCA101 group will receive the investigational drug twice weekly for a total of 8 doses per cycle. Participants in the active control group (megace F suspension) will receive the drug orally once daily. \[Study 2. Placebo-Controlled, Double-Blind Study\] Participants who provide written informed consent will undergo screening procedures. Those who meet all inclusion criteria and none of the exclusion criteria will be eligible for enrollment and will be randomized to receive either ASCA101 (at one of two dose levels: 24.32 or 32.43 mg/kg) or placebo. Participants will receive the investigational product over 3 cycles (12 weeks). Each cycle consists of 28 days. Subjects in the ASCA101 group will receive the investigational drug twice weekly for a total of 8 doses per cycle. Participants in the placebo group will receive placebo in the same manner as the ASCA101 group.
Conditions
- Cachexia; Cancer
Interventions
Active ComparatorDrug
Megace F suspension 625mg(5mL), intake daily for 12weeks
ASCA101 24.32mg/kgDrug
ASCA101 Inj. 24.32mg/kg, twice a week for 12 weeks
ASCA101 32.43mg/kgDrug
ASCA101 Inj. 32.43mg/kg, twice a week for 12 weeks
PlaceboDrug
0.9% normal saline injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in body weight at the end of cycle 3 compared to baselineTime frame: At Screening, baseline(0 week), End of Cycle 1, End of Cycle 2, End of Cycle 3. (Each cycle is 28days.)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, Gangnam-gu, South Korea · Recruiting
National Cancer Center
Gyeonggi-do, Goyang-si, South Korea · Recruiting
Chung-Ang University Gwangmyeong Hospital
Gyeonggi-do, Gwangmyeong-si, South Korea · Recruiting
Seoul ST. Mary's hospital
Seoul, Seocho-gu, South Korea · Recruiting
Korea University Anam Hospital
Seoul, Seongbuk-gu, South Korea · Recruiting
Ajou University Hospital
Gyeonggi-do, Suwon-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.